Thats why we focus on gradual dose adjustments, metabolic support, and long-term strategies to help patients maintain their results
As per FDA approval in 2021, it's indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes mellitus or high cholesterol (hyperlipidemia)
Zepbound was approved a year and a half later, in November 2023, for chronic weight management in adults with obesity as well as those who are overweight and have at least one weight-related condition (like high blood pressure or high cholesterol)
If you are pregnant, breastfeeding, or taking medication[s] please consult your healthcare practitioner before use
Cowling DC, Mackay IR, Taft LI
This study was published in 2008